Suraj Kalia
Stock Analyst at Oppenheimer
(3.83)
# 660
Out of 5,149 analysts
91
Total ratings
47.44%
Success rate
11.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Suraj Kalia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics | Downgrades: Perform | n/a | $25.90 | - | 3 | Feb 26, 2026 | |
| TMDX TransMedics Group | Maintains: Outperform | $150 → $175 | $147.00 | +19.05% | 12 | Feb 25, 2026 | |
| PODD Insulet | Maintains: Outperform | $365 → $300 | $245.45 | +22.22% | 1 | Feb 19, 2026 | |
| ATRC AtriCure | Downgrades: Perform | n/a | $30.93 | - | 8 | Feb 18, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $140 → $132 | $114.12 | +15.67% | 2 | Jan 23, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $125 → $100 | $76.22 | +31.20% | 1 | Jan 16, 2026 | |
| INSP Inspire Medical Systems | Upgrades: Outperform | $175 | $64.81 | +170.02% | 3 | Dec 8, 2025 | |
| VREX Varex Imaging | Maintains: Outperform | $23 → $18 | $13.15 | +36.88% | 7 | Nov 19, 2025 | |
| EW Edwards Lifesciences | Downgrades: Perform | n/a | $87.18 | - | 6 | Oct 8, 2025 | |
| PLSE Pulse Biosciences | Initiates: Outperform | $22 | $18.85 | +16.71% | 1 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $120 | $128.46 | -6.59% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $38.55 | -16.99% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $90 → $93 | $107.40 | -13.40% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $5.01 | +99.60% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $4.02 | +223.38% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $135 | $86.34 | +56.36% | 1 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $257.39 | - | 6 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $29.29 | +2.42% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $320 → $200 | $0.89 | +22,354.25% | 1 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $97 | $80.16 | +21.01% | 1 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $22.52 | +24.33% | 4 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4.5 | $3.85 | +16.88% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.12 | +1,328.57% | 1 | Sep 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $496.25 | - | 3 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $2.46 | - | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $19.69 | +407.87% | 1 | Jun 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $73.78 | - | 5 | Sep 12, 2018 |
PROCEPT BioRobotics
Feb 26, 2026
Downgrades: Perform
Price Target: n/a
Current: $25.90
Upside: -
TransMedics Group
Feb 25, 2026
Maintains: Outperform
Price Target: $150 → $175
Current: $147.00
Upside: +19.05%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $365 → $300
Current: $245.45
Upside: +22.22%
AtriCure
Feb 18, 2026
Downgrades: Perform
Price Target: n/a
Current: $30.93
Upside: -
Abbott Laboratories
Jan 23, 2026
Maintains: Outperform
Price Target: $140 → $132
Current: $114.12
Upside: +15.67%
Boston Scientific
Jan 16, 2026
Maintains: Outperform
Price Target: $125 → $100
Current: $76.22
Upside: +31.20%
Inspire Medical Systems
Dec 8, 2025
Upgrades: Outperform
Price Target: $175
Current: $64.81
Upside: +170.02%
Varex Imaging
Nov 19, 2025
Maintains: Outperform
Price Target: $23 → $18
Current: $13.15
Upside: +36.88%
Edwards Lifesciences
Oct 8, 2025
Downgrades: Perform
Price Target: n/a
Current: $87.18
Upside: -
Pulse Biosciences
Jul 7, 2025
Initiates: Outperform
Price Target: $22
Current: $18.85
Upside: +16.71%
Jan 8, 2025
Maintains: Outperform
Price Target: $105 → $120
Current: $128.46
Upside: -6.59%
Nov 8, 2024
Maintains: Outperform
Price Target: $30 → $32
Current: $38.55
Upside: -16.99%
Nov 1, 2024
Reiterates: Outperform
Price Target: $90 → $93
Current: $107.40
Upside: -13.40%
Sep 16, 2024
Initiates: Outperform
Price Target: $10
Current: $5.01
Upside: +99.60%
Aug 7, 2024
Maintains: Outperform
Price Target: $15 → $13
Current: $4.02
Upside: +223.38%
Jul 16, 2024
Initiates: Outperform
Price Target: $135
Current: $86.34
Upside: +56.36%
Jun 25, 2024
Downgrades: Perform
Price Target: n/a
Current: $257.39
Upside: -
Aug 8, 2023
Maintains: Outperform
Price Target: $24 → $30
Current: $29.29
Upside: +2.42%
Jun 23, 2023
Maintains: Outperform
Price Target: $320 → $200
Current: $0.89
Upside: +22,354.25%
May 16, 2023
Initiates: Outperform
Price Target: $97
Current: $80.16
Upside: +21.01%
Mar 6, 2023
Reiterates: Outperform
Price Target: $28
Current: $22.52
Upside: +24.33%
Nov 29, 2022
Initiates: Outperform
Price Target: $4.5
Current: $3.85
Upside: +16.88%
Sep 24, 2021
Initiates: Outperform
Price Target: $16
Current: $1.12
Upside: +1,328.57%
Apr 21, 2021
Upgrades: Perform
Price Target: n/a
Current: $496.25
Upside: -
Sep 15, 2020
Initiates: Perform
Price Target: n/a
Current: $2.46
Upside: -
Jun 24, 2020
Initiates: Outperform
Price Target: $100
Current: $19.69
Upside: +407.87%
Sep 12, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $73.78
Upside: -